Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
India Glycols's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 32.84.
India Glycols's Days Inventory for the
three
months ended in Mar. 2026 was 133.89.
India Glycols's Days Payable for the
three
months ended in Mar. 2026 was 118.45.
Therefore, India Glycols's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 48.28.
India Glycols (BOM:500201) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
India Glycols Cash Conversion Cycle Related Terms
India Glycols Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for India Glycols's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500201 vs DOW: Cash Conversion Cycle Comparison
For the Chemicals subindustry, India Glycols's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
India Glycols Cash Conversion Cycle vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, India Glycols's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where India Glycols's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
India Glycols's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
India Glycols (BOM:500201) has a Cash Conversion Cycle of 48.28 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on India Glycols and its competitors.
Is India Glycols' Cash Conversion Cycle too high?
India Glycols' current Cash Conversion Cycle is 48.28. The Chemicals industry median Cash Conversion Cycle is 89.43. India Glycols' value of 48.28 is 46% below this industry median. Overall, India Glycols has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does India Glycols' Cash Conversion Cycle compare to DOW?
India Glycols' Cash Conversion Cycle of 48.28 can be compared against companies in the Chemicals industry. The industry median Cash Conversion Cycle is 89.43. India Glycols' value of 48.28 is 46% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Chemicals company?
The median Cash Conversion Cycle among Chemicals companies is 89.43, based on 1,578 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. India Glycols's current Cash Conversion Cycle of 48.28 is 46% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on India Glycols and its competitors. For the Chemicals industry, the median Cash Conversion Cycle is 89.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. India Glycols's current Cash Conversion Cycle is 48.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is India Glycols stock overvalued right now?
Based on GuruFocus' analysis, India Glycols (BOM:500201) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹756.00, compared to a current price of ₹1,090.95 — trading 44.3% above its estimated fair value. The current Cash Conversion Cycle is 48.28 and 46% below the Chemicals industry median of 89.43. India Glycols' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For India Glycols (BOM:500201), the current Cash Conversion Cycle is 48.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is India Glycols (BOM:500201) Overvalued in 2026?
Based on GuruFocus' analysis, India Glycols stock appears to be overvalued.
The current stock price of ₹1,090.95 is trading 44.3% above its estimated GF Value™ of ₹756.00.
GuruFocus considers India Glycols to be Significantly Overvalued.
Key valuation signals for BOM:500201:
Cash Conversion Cycle: 48.28
GF Value™: ₹756.00 vs. price of ₹1,090.95 (44.3% above fair value)
No single metric tells the full story. See the BOM:500201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
India Glycols Ltd is engaged in the manufacture of Bio-Based Specialities and Performance Chemicals, such as green technology-based bulk products, natural gums, and industrial gases; Potable Spirits, and Ennature Biopharma. The company operates through industries of Pharma & Healthcare, Oil & Gas, Textile, Food Ingredients, Automotive, Packaging, Personal Care, Potable Spirits, and Industrial and Manufacturing. Its operating segments are Bio-based Specialities and Performance Chemicals comprise Glycols, Specialty Chemicals, Natural Gum & other related goods, etc; Potable Spirits comprises the manufacture and sale of Ethyl Alcohol (Potable); Ennature Biopharma comprises the manufacture and sale of Nutraceutical Products; and Bio-fuel comprises Ethanol, DDGS & DWGS.
66GF Score
Get the complete analysis for BOM:500201
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500201 has been successfully added to your 
